Murine CD9 Is the Receptor for Pregnancy-specific Glycoprotein 17 by Waterhouse, Roseann et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/01/277/06 $5.00
Volume 195, Number 2, January 21, 2002 277–282
http://www.jem.org/cgi/content/full/195/2/277
 
Brief Deﬁnitive Report
 
277
 
Murine CD9 Is the Receptor for Pregnancy-speciﬁc 
Glycoprotein 17
 
Roseann Waterhouse, Cam Ha, and Gabriela S. Dveksler
 
Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda,
MD 20814
 
Abstract
 
Pregnancy-specific glycoproteins (PSGs) are a family of highly similar secreted proteins pro-
duced by the placenta. PSG homologs have been identified in primates and rodents. Members
of the human and murine PSG family induce secretion of antiinflammatory cytokines in
mononuclear phagocytes. For the purpose of cloning the receptor, we screened a RAW 264.7
cell cDNA expression library. The PSG17 receptor was identified as the tetraspanin, CD9. We
confirmed binding of PSG17 to CD9 by ELISA, flow cytometry, alkaline phosphatase binding
assays, and in situ rosetting. Anti-CD9 monoclonal antibody inhibited binding of PSG17 to
CD9-transfected cells and RAW 264.7 cells. Moreover, PSG17 binding to macrophages from
CD9-deficient mice was significantly reduced. We then tested whether PSG17 binds to other
members of the murine tetraspanin family. PSG17 did not bind to cells transfected with CD53,
CD63, CD81, CD82, or CD151, suggesting that PSG17–CD9 binding is a specific interaction.
We have identified the first receptor for a murine PSG as well as the first natural ligand for a
member of the tetraspanin superfamily.
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Introduction
 
Pregnancy-specific glycoproteins (PSGs) are a family of
highly similar, placentally secreted proteins, originally iso-
lated from the circulation of pregnant women (1). PSGs are
members of the carcinoembryonic antigen (CEA) family
and in humans, PSG concentration in the bloodstream in-
creases exponentially until term (2). Low levels of PSGs are
associated with pathological conditions including spontane-
ous abortion, intrauterine growth retardation, and pre-
eclampsia (3, 4). Administration of anti-PSG Abs induced
spontaneous abortion in primates, indicating that PSGs are
essential for successful pregnancy (5). Recently, we dem-
onstrated that human PSGs induced IL-10, IL-6, and
TGF
 
 
 
1
 
 expression in human monocytes (6). This suggests
that PSGs, through induction of these Th2 cytokines, may
have a role in protecting the fetus from attack by the ma-
ternal immune system.
Despite their isolation from maternal serum 30 years ago,
the receptor(s) for these proteins has not yet been identi-
fied. PSGs have also been identified in nonprimates with
hemochorial placentation including rats and mice. There
are 14 murine PSG genes (
 
PSG14–29
 
; reference 7) and the
cDNAs that have been characterized showed exclusive ex-
pression by the placenta (8).
We recently reported that murine PSG17 and PSG18
mimic the biological effects of human PSGs, by inducing
cytokines in murine macrophages and the RAW 264.7
macrophage cell line (9) and unpublished data. In addition,
we showed that PSG17 binds to RAW cells with high affin-
ity (unpublished data). For the purpose of cloning the
PSG17 receptor, we screened a RAW cell cDNA expression
library by panning. Positive clones were sequenced, and da-
tabase queries revealed that the receptor for PSG17 is the
tetraspanin CD9.
Sequence analysis of CD9 suggests that like other tet-
raspanins, it has four hydrophobic transmembrane domains
and two extracellular loops, with two short intracytoplas-
mic tails at the amino and carboxyl termini (10, 11). In the
membrane, CD9 associates with other tetraspanin family
members (12, 13) and with 
 
 
 
1
 
 integrins (14–17). Other cell
surface molecules present in tetraspanin complexes include
HLA-DR and MHC class II glycoproteins, CD4, CD8,
CD19, and a 135-kD protein designated CD9 partner 1
(12, 13, 18–21). Treatments with Abs to different tet-
raspanins have implicated these proteins in cell migration,
proliferation, activation, and adhesion (18). With such po-
tentially diverse roles, they have been described as “molec-
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ular facilitators.” This is the first report to identify the bind-
ing partner for a PSG family member, as well as a biological
ligand for a member of the tetraspanin superfamily.
 
Materials and Methods
 
Reagents.
 
Recombinant PSG17N-Myc-His, which consists
of the leader peptide, N1 domain of PSG17 (formerly known as
Cea 2), followed by the Myc and 6X His tags was generated using
a baculovirus expression system and purified as described previ-
ously (6, 9). Transfections were performed with Lipofectamine
2000 (Invitrogen) and transfection efficiency was monitored us-
ing a plasmid encoding the green fluorescent protein.
The murine CD53 and CD82 cDNAs were amplified by re-
verse transcription (RT)-PCR from RAW cell RNA and the
murine CD81 cDNA was amplified from pBluescript containing
the CD81 cDNA. The primer sets used for the amplifications
were: for CD53: 5
 
 
 
ATGGGCATGAGCAGCCTGAAA and
5
 
 
 
TCACAGCCCTAAAGCCTGGC; for CD82: 5
 
 
 
CAGAA-
TGGGGGCAGGCTGTG and 5
 
 
 
CAGCAACCTCAGTAC-
TTGGGG; for CD81: 5
 
 
 
ATGGGGGTGGAGGGCTGC and
5
 
 
 
TCAGTACACGGAGCTGTTCCGG. After amplification with
Vent DNA polymerase, the cDNAs were cloned into pEF6/
V5-His Topo (Invitrogen), colonies were probed with oligonu-
cleotides specific for each tetraspanin and the correct orientation
was confirmed. The murine CD151 cDNA in pcDNA3.1 Zeo
was obtained from Dr. L. Ashman, The Hanson Centre for
Cancer Research, Adelaide, Australia, and the murine CD63
cDNA in pcDNA3.1/GS was purchased from Research Ge-
netics.
PSG17N-Myc-His–coated plates were prepared as follows.
Bacteriological culture dishes were layered with 10 
 
 
 
g/ml goat
anti–mouse IgG, extra serum absorbed (XSA; KPL) in phosphate
coating solution (KPL). The plates were rinsed with PBS and
blocked with BSA buffer (KPL). Anti-myc mAb (1 
 
 
 
g/ml) (In-
vitrogen) was added to each dish followed by the addition of
PSG17N-Myc-His with washes after each step.
 
Cell Culture.
 
RAW 264.7 (American Type Culture Collec-
tion) cells were cultured in DMEM with high glucose, 5 mM so-
dium pyruvate (Irvine Scientific), 100 U/ml penicillin, 100 
 
 
 
g/
ml streptomycin, 0.25 
 
 
 
g/ml amphotericin B (PSA; Quality Bio-
logical), and 10% fetal bovine serum (FBS). Human embryonic
kidney (HEK) 293T cells (Edge BioSystems) were cultured in
DMEM, 10% FBS, 50 
 
 
 
g/ml gentamicin, 250 
 
 
 
g/ml G418
(Calbiochem), and PSA. HEK 293 EBNA cells (Invitrogen) were
grown in DMEM, 10% FBS, PSA, and 250 
 
 
 
g/ml G418. Baby
hamster kidney (BHK)–21 cells (American Type Culture Collec-
tion) were sustained in DMEM with 10% FBS and PSA. All cell
cultures were maintained at 37
 
 
 
C in a humidified atmosphere
containing 5% CO
 
2
 
.
 
Generation of the RAW 264.7 cDNA Library and Recovery of
cDNA Clones by Panning.
 
RNA was extracted from RAW
264.7 cells using TRIzol (Invitrogen) and was used to generate
the cDNA expression library in the PEAK10CV vector (Edge
BioSystems). The unamplified library yielded 
 
 
 
4.3 
 
 
 
 10
 
6
 
 pri-
mary transformants. For the first round of screening, 1.1 
 
 
 
 10
 
6
 
clones were plated on Luria-Bertani (LB) broth/agar plates with
100 
 
 
 
g/ml ampicillin (Sigma-Aldrich). After 16 h the plates were
flooded with LB broth, the pooled bacteria were pelleted, and
plasmid DNA was isolated.
Pooled purified plasmids from the library were transfected into
HEK 293 EBNA cells. Positive transfectants were selected using
0.5 
 
 
 
g/ml puromycin (Edge BioSystems). At 72 h after selection,
the cells were dislodged in PBS and 0.5 mM EDTA, and resus-
pended in binding buffer (PBS, 2% BSA). The detached cells
were panned in PSG17N-Myc-His coated Petri dishes at 1.0–
1.5 
 
 
 
 10
 
7
 
 cells per dish. Non-adherent cells were removed by
extensive washing with PBS/BSA and adherent cells were trans-
ferred to poly-L-lysine coated 96-well plates. An additional two
rounds of panning were performed before the episomal plasmids
were isolated and transformed into ElectroMAX™ DH10B cells
(Invitrogen). Individual plasmids were purified and transfected
into HEK 293T cells, after which the transfected cells were
screened for their ability to bind PSG17N-Myc-His by ELISA
(see below). Inserts from the plasmids that conferred PSG17N
binding were sequenced with the ABI PRISM Big Dye Termi-
nator Cycle Sequencing Ready Reaction Kit (PE Biosystems).
 
Detection of PSG17 Binding to Transfected HEK 293T Cells by
ELISA.
 
HEK 293T cells were seeded in poly-L-lysine coated
96-well plates at 5 
 
 
 
 10
 
4
 
 cells per well and transiently transfected
with plasmid DNA recovered after library screening as described
above or encoding the CD53, CD63, CD81, CD82, or CD151
cDNAs. At 48 h after transfection, the cells were washed with
binding buffer containing 0.01% sodium azide and PSG17N-
Myc-His (10 
 
 
 
g/ml) or no ligand was added to each well. After 1 h
of incubation at room temperature, the ligand was aspirated and
the cells were washed five times with binding buffer without so-
dium azide. To detect binding of PSG17N-Myc-His, anti-myc-
horseradish peroxidase (HRP)-conjugated mAb was added to the
cells for 1 h at room temperature at a concentration of 1 
 
 
 
g/ml
in binding buffer. Binding of the antibody to the ligand was de-
tected after the addition of tetramethylbenzidine (TMB)-peroxi-
dase substrate (KPL) followed by 2 N H
 
2
 
SO
 
4
 
. The color change
was quantitated at 450 nm on a microplate spectrophotometer.
Competition experiments were performed in CD9-pEF6/V5-
His (Invitrogen) transfected HEK 293T cells by adding increasing
concentrations of anti-murine CD9 mAb KMC8.8 (BD Phar-
Mingen) or an isotype-matched control (rat IgG
 
2a
 
) for 1 h at
room temperature before treatment with 5 
 
 
 
g/ml PSG17N. Ab-
sorbance was normalized to background binding of PSG17N in
the presence of anti-CD9 mAb to empty plasmid transfected
HEK 293T cells.
 
In Situ Rosetting Assay.
 
For the in situ rosetting assay, HEK
293T cells transiently transfected with empty vector or CD9-
pEF6/V5-His were seeded at low density into poly-L-lysine
coated 60-mm dishes (Becton Dickinson). Attached cells were
washed in binding buffer (PBS-2% BSA). PSG17N-Myc-His (90
pM) or binding buffer alone was added to the dishes for 1 h at
room temperature. The cells were washed four times with PBS
to remove any unbound ligand before the addition of 1 
 
 
 
g/ml
anti-myc mAb in binding buffer for 1 h at room temperature. As
a control, the anti-myc mAb was omitted from some plates.
Dishes were washed again with PBS before the addition of 15 
 
 
 
g
of rabbit anti–mouse Ig coated beads (Bio-Rad Laboratories).
Unbound beads were removed by washing extensively with PBS
and receptor positive cells were viewed by microscopy.
 
Flow Cytometry.
 
HEK 293T or BHK-21 cells were trans-
fected with murine CD9-pEF/V5-His or empty vector. 48 h af-
ter transfection, the cells were washed twice with wash buffer
(PBS; 3% FBS; 0.01% sodium azide), before the addition of 10
 
 
 
g PSG17N-Myc-His for 30 min at room temperature. After
two washes, cells were sequentially incubated for 30 min on ice
with 0.5 
 
 
 
g anti-myc mAb (Invitrogen), 0.5 
 
 
 
g biotin-labeled
goat anti–mouse IgG
 
2a
 
 
 
 (BD PharMingen) and 0.5 
 
 
 
g streptavidin-
FITC (BD PharMingen) with two washes between each incuba- 
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tion. For inhibition experiments, 10
 
6
 
 RAW 264.7 cells were pre-
incubated with 1 
 
 
 
g of Fc block (BD PharMingen) and various
concentrations of anti-CD9 mAb or isotype control mAb for 30
min on ice. After several washes, 2 
 
 
 
g of PSG17N-Myc-His
were added to each tube followed by 0.7 
 
 
 
g of anti-myc mAb,
and PE-labeled rat anti–mouse IgG1 (BD PharMingen). Binding
of PSG17N-Myc-His to thioglycollate-induced peritoneal mac-
rophages isolated from CD9-deficient mice or wild-type mice
was determined after 24 h treatment of the macrophages with 10
ng/ml PMA followed by incubation with Fc block, PSG17N or a
control myc-tagged protein, anti-myc mAb, and PE-labeled rat
anti–mouse IgG1 as described above for the RAW cells.
PSG17N binding to HEK 293T, BHK 21, RAW 264.7 cells and
macrophages was analyzed by flow cytometry using an EPICS
XL-MCL flow cytometer (Beckman Coulter) and the percent
binding was determined with the System II Software program
(Beckman Coulter). Overlays were produced with the WinList
program (Verity Software House).
 
Alkaline Phosphatase Binding Assays.
 
The PSG17-alkaline
phosphatase (PSG17-AP) fusion protein was generated by clon-
ing the full length PSG17 cDNA into the AP-Tag 4 vector. CD9
binding assays with heat stable AP-PSG17 were performed as de-
scribed by Flanagan and Cheng (22). Briefly, HEK 293T cells
transiently transfected with murine CD9 or empty vector were
cultured in poly-L-lysine–coated six-well plates. Increasing con-
centrations (43, 86, and 129 nM) of AP-PSG17 or the AP con-
trol protein were added to each well in triplicate for 90 min at
room temperature. The cells were thoroughly washed, and the
concentration of bound protein was measured from cleared, heat-
inactivated cell lysates with dephosphorylation of p-nitrophenyl
phosphate, which was quantitated by absorption at 405 nm using
an ELISA plate reader.
 
Results and Discussion
 
Identification of CD9 as the Cellular Receptor for PSG17.
 
To isolate the PSG17 receptor, a RAW cell cDNA library
was generated (Edge BioSystems) and plasmid DNA was
transfected into HEK 293 EBNA cells, 72 h before panning
on PSG17N-coated dishes. After three rounds of panning,
plasmid DNA was isolated and electroporated into electro-
competent 
 
Escherichia
 
 
 
coli
 
. Plasmids isolated from individual
bacterial colonies were transfected into HEK 293T cells
and their ability to confer PSG17 binding was determined
by ELISA. All positive clones were sequenced and database
queries identified a perfect match between these cDNAs
and murine CD9.
To confirm binding of PSG17 to CD9, CD9-pEF6/
V5-His–transfected HEK 293T cell were treated with
PSG17N-Myc-His and analyzed by ELISA. PSG17N-
Myc-His was shown to bind CD9-transfected cells in a
dose response manner with a binding plateau at 10 
 
 
 
g/ml
(Fig. 1 A). Rosetting experiments further confirmed
binding of PSG17N-Myc-His to CD9. CD9-pEF6/V5-
His–transfected cells treated with PSG17N-Myc-His and
anti-myc mAb followed by rabbit anti–mouse Ig immu-
nobeads showed a rosetting pattern. This pattern was not
observed in the control dishes, lacking PSG17N treat-
ment, anti-myc mAb, or expression of CD9 (data not
shown).
 
To demonstrate specific binding between PSG17N and
murine CD9, competition ELISAs were performed in
HEK 293T cells transfected with empty vector or CD9-
pEF6/V5-His (Fig. 1 B). 48 h after transfection, anti-CD9
mAb or a matched isotype control mAb were added fol-
lowed by PSG17N-Myc-His. The addition of 10 
 
 
 
g/ml
anti-CD9 mAb reduced PSG17N binding to background
levels. PSG17 binding to CD9 was also analyzed by flow
cytometry (Fig. 2). HEK 293T cells were transfected with
CD9-pEF6/V5-His or empty vector. To determine extent
of expression of CD9 in the transfected cells, the cells were
treated with biotin-labeled anti-CD9 mAb or a matched
isotype control biotin-labeled mAb. Approximately 70% of
the cells stained positive for CD9 (data not shown). The
percentage of cells that stained positive for PSG17 binding
to CD9-transfected cells ranged from 66–87% while there
was 
 
 
 
1% binding to the empty vector transfected cells
(Fig. 2 A).
Screening of the library by panning and the binding ex-
periments described above were all performed using HEK
293 cells. To examine whether PSG17 binds to CD9 on
cells of a different species, we transfected BHK-21 cells
with CD9-pEF6/V5-His. The results show significant
binding of the PSG17N to CD9-transfected BHK-21 cells
(
 
 
 
97%) compared with controls (
 
 
 
5%) suggesting that
CD9 expression may be sufficient for PSG17N binding in
any cell type (Fig. 2 B).
Figure 1. Binding of PSG17N to murine CD9-transfected 293T cells
and inhibition of PSG17 binding to CD9 expressing cells by anti-CD9
mAb. (A) HEK 293T cells were transfected with CD9-pEF6/V5-His or
empty plasmid after which they were incubated with varying concentra-
tions of PSG17N-Myc-His. (B) HEK 293T-CD9-pEF/V5-His trans-
fected cells were treated with increasing concentrations of anti-CD9 mAb
or an isotype-matched control mAb before the addition of PSG17N-
Myc-His (5  g/ml). Bound PSG17N-Myc-His was detected after treat-
ment with HRP-conjugated anti-myc mAb and TMB/peroxidase sub-
strate. The data is expressed as mean absorbance   SE. Each data point
represents five identical wells and the experiment was repeated three in-
dependent times with similar results. 
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Binding of Alkaline Phosphatase-PSG17 (AP-PSG17) to
CD9-expressing Cells.
 
For the library screening and the
binding experiments described above we used a trun-
cated form of PSG17 consisting only of the N1-domain.
 
We examined binding of the full length PSG17 to
murine CD9 using a rAP-PSG17 fusion protein. HEK
293T cells transiently transfected with CD9-pEF6/V5-His
were treated with increasing concentrations of AP-
PSG17 or an AP control protein (Table I). AP-PSG17
binding to CD9 transfected cells was concentration de-
pendent while binding of the AP-control protein re-
mained at baseline levels
 
. Figure 2. FACS® analysis of PSG17N-Myc-His binding to CD9-trans-
fected HEK 293T cells and BHK-21 cells. HEK 293T cells (A) and BHK-21
(B) cells transfected with empty plasmid (dotted line) or murine CD9-pEF6/
V5-His; solid line) were treated with PSG17N-Myc-His, anti-myc mAb, bi-
otin-conjugated goat anti–mouse IgG2a , and FITC-conjugated streptavidin.
Figure 3. FACS® analysis of PSG17 binding to RAW 264.7 cells pre-
treated with anti-CD9 mAb KMC8.8. RAW 264.7 cells were incubated
with Fc block after which they were treated with anti-CD9 mAb
KMC8.8 (dotted line), an isotype match control mAb (filled line), or no
Ab (shaded area) before the addition of PSG17N-Myc-His (dotted and
filled lines), or a control myc-tagged protein (shaded area). Binding was
detected by the sequential addition of anti-myc mAb and PE-labeled rat
anti–mouse IgG1.
 
Table I.
 
Full-length PSG17 Binds to CD9-transfected Cells
 
Protein
treatment AP-control bound AP-PSG17 bound
 
nM pM pM
 
43.5 49.0 
 
  
 
20.8 701.7 
 
  
 
43.3
87.1 54.8 
 
  
 
17.3 3,564.3 
 
  
 
39.8
130.6 61.2 
 
  
 
8.7 5,956.4 
 
  
 
74.5
HEK 293T cells transfected with CD9-pEF6/V5-His were treated with
increasing concentrations of AP-PSG17 or the AP-control protein.
Each experiment was done in triplicate and the data points represent the
mean concentration bound.
Figure 4. FACS® analysis of PSG17 binding to peritoneal macrophages
isolated from CD9-deficient and wild-type mice. Peritoneal macrophages
isolated from wild-type mice (dotted line) or CD9-deficient mice (solid
line) were sequentially incubated with Fc block, PSG17N-Myc-His,
anti-myc mAb, and PE-labeled rat anti–mouse IgG1. 
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Murine PSG17 Does Not Bind to the Murine Tetraspanins
CD53, CD63, CD81, CD82, and CD151.
 
To deter-
mine whether PSG17 used other members of the tetraspa-
nin family as binding partners, murine CD53, CD63,
CD81, CD82, and CD151 were transfected into HEK
293T and the cells were incubated with PSG17N-Myc-
His. PSG17N did not show significant binding to the five
tetraspanins tested in the ELISA assay (data not shown). At
this point, we cannot conclude whether other members of
the tetraspanin family, which we have not yet tested, could
serve as receptors for murine PSG17 or whether the bind-
ing of PSG17 to the murine tetraspanins tested is of low af-
finity and cannot be detected in the assay we employed.
 
CD9 Is the Receptor for PSG17 in RAW 264.7 Cells and
Macrophages.
 
Scatchard analysis revealed that PSG17 has a
single binding site in RAW 264.7 cells and murine macro-
phages (unpublished data). To determine whether this
binding site is CD9, RAW 264.7 cells were pretreated with
anti-CD9 mAb KMC8.8 or an isotype match control mAb
before the addition of PSG17N-Myc-His and binding was
determined by flow cytometry. Preincubation with 40 
 
 
 
g/
ml of anti-CD9 mAb resulted in a significant reduction in
median fluorescence intensity when compared with the
median fluorescence intensity of the cells pretreated with
the control isotype match mAb (Fig. 3). In addition, the
extent of the inhibition of PSG17 binding to RAW 264.7
cells by the anti-CD9 mAb was dependent on the concen-
tration of the anti-CD9 mAb employed (data not shown).
Binding of PSG17 to macrophages isolated from CD9-
deficient mice was reduced to almost background levels,
defined as the binding of a control myc-tagged protein
(data not shown), and was significantly lower than the
binding of PSG17 to macrophages of wild-type mice (Fig.
4). Based on these and our previous results (unpublished
data), we conclude that CD9 is the only receptor in macro-
phages and that binding of PSG17 to CD9 results in the se-
cretion of cytokines.
Signaling molecules associated with CD9 include phos-
phatidylinositol 4-kinase and protein kinase C (23, 24).
PSG17 could signal induction of cytokines by means of a
variety of interactions with any of these molecules or others
(18). To date, the proteins associated with CD9 in murine
macrophages have not been identified although a func-
tional association of CD9 with Fc
 
 
 
 receptors in murine
macrophages has been reported (25).
CD9
 
 
 
/
 
 
 
 have reduced female fertility linked to a defect
in egg/sperm fusion (26, 27). CD9
 
 
 
/
 
 
 
 mice produce some
viable fetuses, indicating that CD9 is important for fertiliza-
tion but is not essential for pregnancy success. Whether all
murine PSGs use CD9 as their cellular receptor remains to
be investigated. Different murine PSGs may have evolved
to use different receptors and no single PSG may be essen-
tial for pregnancy success. In addition, we anticipate that
pregnancy complications associated with lack of PSG-
mediated cytokine secretion would be demonstrated in
matings of mice with different genetic backgrounds.
Because CD9 is expressed in several cells of the immune
system, including: macrophages, dendritic cells (data not
 
shown), and T cells (28), PSGs have a potential role in reg-
ulating both the innate as well as the adaptive immune re-
sponses during pregnancy.
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